ziritaxestat (GLPG1690) / Galapagos, Gilead  >>  Phase 1
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ziritaxestat (GLPG1690) / Galapagos, Gilead
NCT02179502: First-in-Human Single and Multiple Dose of GLPG1690

Completed
1
40
Europe
GLPG1690 single ascending doses, Placebo single ascending doses, GLPG1690, multiple ascending doses, oral suspension, Placebo, multiple ascending doses, oral suspension
Galapagos NV
Healthy
11/14
12/14
NCT03143712: Study to Assess Bioavailability of GLPG1690 Given as Oral Capsule or Tablet

Completed
1
12
Europe
GLPG1690
Galapagos NV
Healthy
06/17
06/17
NCT03515382: A Study in Healthy Male Volunteers to Look at How the Test Medicine GLPG1690 is Taken up by the Body When Doses of Itraconazole and Voriconazole Are Given to Healthy Volunteers

Completed
1
18
Europe
GLPG1690, Itraconazole, Voriconazole
Galapagos NV
Healthy
06/18
06/18
NCT03787186: A Study in Healthy Male Volunteers to Look at How the Test Medicine GLPG1690 is Taken up by the Body When Given by Mouth and Into a Vein as an Injection

Completed
1
8
Europe
GLPG1690 film-coated tablets, [14C]-GLPG1690 solution for infusion, [14C]-GLPG1690 capsules
Galapagos NV
Healthy
01/19
01/19

Download Options